CLEC14A and neoplasm: Interestingly, we also found that our antibody not only effectively suppresses tumor angiogenesis in the in vivo angiogenesis mouse models of HCT116 colorectal cancer cell lines, but also in those of bevacizumab-resistant HCT116-derived tumor cells, suggesting that antibody targeting of the CLEC14a CTLD may be an effective strategy to improve treatment options for bevacizumab-resistant tumors [212].